Objective·To investigate the bidirectional causal relationships between celiac disease(CeD)and Hashimoto thyroiditis(HT)as well as Graves disease(GD),using a two-sample Mendelian randomization(MR)approach.Methods·Single nucleotide polymorphisms(SNPs)related to CeD,HT and GD were extracted from publicly available Genome-Wide Association Studies(GWAS)databases and used as instrumental variables.The inverse-variance weighted(IVW)method served as the primary analytical approach,supplemented by MR-Egger,weighted median(WME)and weighted mode(WMO)methods,to evaluate the causal associations between CeD and both HT and GD.Replication analyses using alternative GWAS datasets were conducted to validate the robustness of the results.Heterogeneity was assessed using Cochran's Q test,and pleiotropy was evaluated via MR-Egger intercept test.Leave-one-out analyses were performed to assess the impact of individual SNPs on the results.Results·The IVW analysis results indicated that genetically predicted CeD significantly increased the risk of HT[discovery group:OR=1.186(95%CI 1.114?1.262),P<0.001;replication group:OR=1.218(95%CI 1.090?1.361),P<0.001]and GD[discovery group:OR=1.214(95%CI 1.155?1.276),P<0.001;replication group:OR=1.273(95%CI 1.161?1.396),P<0.001].However,reverse MR analyses did not provide evidence for a causal relationship between HT and CeD,while genetically predicted GD significantly increased the risk of CeD[discovery group:OR=1.259(95%CI 1.006?1.576),P=0.044;replication group:OR=1.387(95%CI 1.233?1.560),P<0.001].Sensitivity analyses suggested that the results were not influenced by horizontal pleiotropy.Conclusion·CeD may be causally associated with a higher risk of HT and GD,while GD may increase the risk of developing CeD.HT does not appear to have an impact on CeD.

Objective·To investigate the bidirectional causal relationships between celiac disease(CeD)and Hashimoto thyroiditis(HT)as well as Graves disease(GD),using a two-sample Mendelian randomization(MR)approach.Methods·Single nucleotide polymorphisms(SNPs)related to CeD,HT and GD were extracted from publicly available Genome-Wide Association Studies(GWAS)databases and used as instrumental variables.The inverse-variance weighted(IVW)method served as the primary analytical approach,supplemented by MR-Egger,weighted median(WME)and weighted mode(WMO)methods,to evaluate the causal associations between CeD and both HT and GD.Replication analyses using alternative GWAS datasets were conducted to validate the robustness of the results.Heterogeneity was assessed using Cochran's Q test,and pleiotropy was evaluated via MR-Egger intercept test.Leave-one-out analyses were performed to assess the impact of individual SNPs on the results.Results·The IVW analysis results indicated that genetically predicted CeD significantly increased the risk of HT[discovery group:OR=1.186(95%CI 1.114?1.262),P<0.001;replication group:OR=1.218(95%CI 1.090?1.361),P<0.001]and GD[discovery group:OR=1.214(95%CI 1.155?1.276),P<0.001;replication group:OR=1.273(95%CI 1.161?1.396),P<0.001].However,reverse MR analyses did not provide evidence for a causal relationship between HT and CeD,while genetically predicted GD significantly increased the risk of CeD[discovery group:OR=1.259(95%CI 1.006?1.576),P=0.044;replication group:OR=1.387(95%CI 1.233?1.560),P<0.001].Sensitivity analyses suggested that the results were not influenced by horizontal pleiotropy.Conclusion·CeD may be causally associated with a higher risk of HT and GD,while GD may increase the risk of developing CeD.HT does not appear to have an impact on CeD.

The Chinese Pharmacopoeia 2025 Edition added the 9213 Guideline for validation,verification,and transfer of microbiological analytical methods.Based on the characteristics of pharmaceutical microbiological analyt-ical methods and practical applications,it specified definitions of relevant terms and application scenarios,estab-lished technical indicators and acceptance criteria for methodological evaluation,and introduced key statistical tools and evaluation principles.This article systematically elaborates on the drafting background and process of the Guideline,and interprets its key content,aiming to offer theoretical guidance and practical reference for relevant practitioners in applying this guideline.This guideline strengthens the foundation of pharmaceutical microbial analytical methods in China and enhances the scientificity and accuracy of the pharmaceutical microbial standards system.

The Chinese Pharmacopoeia 2025 Edition added the 9213 Guideline for validation,verification,and transfer of microbiological analytical methods.Based on the characteristics of pharmaceutical microbiological analyt-ical methods and practical applications,it specified definitions of relevant terms and application scenarios,estab-lished technical indicators and acceptance criteria for methodological evaluation,and introduced key statistical tools and evaluation principles.This article systematically elaborates on the drafting background and process of the Guideline,and interprets its key content,aiming to offer theoretical guidance and practical reference for relevant practitioners in applying this guideline.This guideline strengthens the foundation of pharmaceutical microbial analytical methods in China and enhances the scientificity and accuracy of the pharmaceutical microbial standards system.

Objective To investigate the susceptibility of Cryptococcus neoformans strains to antifungal drugs and examine the relevant clinical manifestations and laboratory test results in a tertiary hospital in Shanghai during the period from 2019 to 2023.Methods The isolates were identified by MALDI-TOF and biochemical identification cards.The minimum inhibitory concentration(MIC)values of 5-fluorocytosine,amphotericin B,fluconazole,voriconazole,and itraconazole against C.neoformans strains were measured using broth microdilution method.The corresponding clinical data were reviewed and compared.Results Majority(78.7％)of the 75 strains of C.neoformans were isolated from cerebrospinal fluid(CSF).The prevalence of wild type(WT)strains was the lowest(36.0％)for itraconazole and the highest(94.7％)for voriconazole.Cryptococcus capsular antigen test was positive in 62 strains.The results of Cryptococcus capsular antigen test was consistent with fungal culture in 96.9％of the cases.Conclusions Most of the C.neoformans strains were isolated from CSF.The prevalence of non-WT C.neoformans strains was the highest for itraconazole.The prevalence of WT C.neoformans strains was the highest for voriconazole.

Objective To investigate and analyze the association of serum levels of myelin basic protein(MBP)and S100 calcium-binding protein B(S100-B)with early neurological deterioration in patients with cerebral infarction after interventional therapy.Methods A total of 258 patients with cerebral infarction,admitted to our hospital between July 2021 and July 2024,were enrolled.The National Institutes of Health Stroke Scale(NIHSS)was used to evaluate the neurological function status of patients.Patients who died or whose NIHSS score increased by 4 points or more after 24 hours of interventional therapy were included in the early neurological deterioration group,while the remaining patients were included in the non-deterioration group.The levels of MBP and S100-B in all patients were measured,and the relationship between changes in MBP and S100-B levels and the risk of neurological deterioration after interventional therapy was analyzed.Results The levels of serum MBP and S100-B of patients with cerebral infarction were markedly higher in the early neurological deterioration group compared with those in the non-deterioration group(t=9.062[95%CI:2.348-3.663]and 7.708[95%CI:0.221-0.375],P<0.001).Spearman correlation analysis showed that the levels of serum MBP and S100-B in the deterioration group were positively correlated with NIHSS score increase(r=0.323[95%CI:0.095-0.542]and 0.292[95%CI:0.066-0.488],P<0.05).Stratified regression analysis showed that serum MBP(OR=1.996,95%CI:1.607-2.478)and S100-B(OR=1.005,95%CI:1.003-1.007)were risk factors affecting the early deterioration of neurological function in patients with cerebral infarction(P<0.05),even after adjusting for confounding factors.In addition,admission NIHSS score(OR=1.224,95%CI:1.142-1.310),hypertension(OR=2.542,95%CI:1.139-5.669)and hyperlipidemia(OR=2.618,95%CI:1.101-6.228)were also risk factors,and an interaction effect between the admission NIHSS score and MBP(OR=1.081,95%CI:1.034-1.130)was observed.Receiver operating characteristic(ROC)curve analysis showed that the area under the curve(AUC)of serum MBP and S100-B in evaluating early neurological deterioration were 0.822(95%CI:0.764-0.879)and 0.788(95%CI:0.724-0.853),respectively.Conclusion Elevated levels of serum MBP and S100-B in patients with cerebral infarction after interventional therapy are associated with an increased risk of early neurological deterioration and show potential value for assessing the risk of neurological deterioration.

Objective To investigate the susceptibility of Cryptococcus neoformans strains to antifungal drugs and examine the relevant clinical manifestations and laboratory test results in a tertiary hospital in Shanghai during the period from 2019 to 2023.Methods The isolates were identified by MALDI-TOF and biochemical identification cards.The minimum inhibitory concentration(MIC)values of 5-fluorocytosine,amphotericin B,fluconazole,voriconazole,and itraconazole against C.neoformans strains were measured using broth microdilution method.The corresponding clinical data were reviewed and compared.Results Majority(78.7％)of the 75 strains of C.neoformans were isolated from cerebrospinal fluid(CSF).The prevalence of wild type(WT)strains was the lowest(36.0％)for itraconazole and the highest(94.7％)for voriconazole.Cryptococcus capsular antigen test was positive in 62 strains.The results of Cryptococcus capsular antigen test was consistent with fungal culture in 96.9％of the cases.Conclusions Most of the C.neoformans strains were isolated from CSF.The prevalence of non-WT C.neoformans strains was the highest for itraconazole.The prevalence of WT C.neoformans strains was the highest for voriconazole.

Polycystic ovary syndrome (PCOS) is a reproductive endocrine disorder that is more common in women of childbearing age, which seriously affects women's quality of life and fertility, taking a toll on both physical and mental health as well as economic capacity. At present, the problems of thin ovulation and endocrine disorders in PCOS patients can be corrected by fertility drugs, but the endometrial receptivity of the patients is still in a poor state, and there is still a situation of inability to conceive. Current studies have shown that endometrial receptivity defects in PCOS patients are closely related to abnormal expression of metabolism, immunity, hormones and their receptors, etc. However, the specific pathological mechanism and etiology have not been fully clarified. This paper mainly discusses the factors of endometrial receptivity defects in patients with PCOS, and focuses on three aspects: genetic and epigenetic abnormalities, metabolic abnormalities, and immune disorders, trying to provide some clues for future treatment options and new drug targets for PCOS patients.

Polycystic ovary syndrome (PCOS) is a reproductive endocrine disorder that is more common in women of childbearing age, which seriously affects women's quality of life and fertility, taking a toll on both physical and mental health as well as economic capacity. At present, the problems of thin ovulation and endocrine disorders in PCOS patients can be corrected by fertility drugs, but the endometrial receptivity of the patients is still in a poor state, and there is still a situation of inability to conceive. Current studies have shown that endometrial receptivity defects in PCOS patients are closely related to abnormal expression of metabolism, immunity, hormones and their receptors, etc. However, the specific pathological mechanism and etiology have not been fully clarified. This paper mainly discusses the factors of endometrial receptivity defects in patients with PCOS, and focuses on three aspects: genetic and epigenetic abnormalities, metabolic abnormalities, and immune disorders, trying to provide some clues for future treatment options and new drug targets for PCOS patients.